tetano
Editor, Senior Moderator
BMJ
. 2021 Feb 11;372:n311.
doi: 10.1136/bmj.n311.
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Christopher T Rentsch[SUP] 1 2 [/SUP], Joshua A Beckman[SUP] 3 [/SUP], Laurie Tomlinson[SUP] 4 [/SUP], Walid F Gellad[SUP] 5 6 7 [/SUP], Charles Alcorn[SUP] 8 [/SUP], Farah Kidwai-Khan[SUP] 2 9 [/SUP], Melissa Skanderson[SUP] 2 [/SUP], Evan Brittain[SUP] 10 [/SUP], Joseph T King Jr[SUP] 2 11 [/SUP], Yuk-Lam Ho[SUP] 12 [/SUP], Svetlana Eden[SUP] 13 [/SUP], Suman Kundu[SUP] 14 [/SUP], Michael F Lann[SUP] 8 [/SUP], Robert A Greevy Jr[SUP] 15 [/SUP], P Michael Ho[SUP] 16 [/SUP], Paul A Heidenreich[SUP] 17 18 [/SUP], Daniel A Jacobson[SUP] 19 [/SUP], Ian J Douglas[SUP] 4 [/SUP], Janet P Tate[SUP] 2 9 [/SUP], Stephen J W Evans[SUP] 4 [/SUP], David Atkins[SUP] 20 [/SUP], Amy C Justice[SUP] 2 9 21 [/SUP], Matthew S Freiberg[SUP] 14 22 [/SUP]
Affiliations
Abstract
Objective: To evaluate whether early initiation of prophylactic anticoagulation compared with no anticoagulation was associated with decreased risk of death among patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United States.
Design: Observational cohort study.
Setting: Nationwide cohort of patients receiving care in the Department of Veterans Affairs, a large integrated national healthcare system.
Participants: All 4297 patients admitted to hospital from 1 March to 31 July 2020 with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and without a history of anticoagulation.
Main outcome measures: The main outcome was 30 day mortality. Secondary outcomes were inpatient mortality, initiating therapeutic anticoagulation (a proxy for clinical deterioration, including thromboembolic events), and bleeding that required transfusion.
Results: Of 4297 patients admitted to hospital with covid-19, 3627 (84.4%) received prophylactic anticoagulation within 24 hours of admission. More than 99% (n=3600) of treated patients received subcutaneous heparin or enoxaparin. 622 deaths occurred within 30 days of hospital admission, 513 among those who received prophylactic anticoagulation. Most deaths (510/622, 82%) occurred during hospital stay. Using inverse probability of treatment weighted analyses, the cumulative incidence of mortality at 30 days was 14.3% (95% confidence interval 13.1% to 15.5%) among those who received prophylactic anticoagulation and 18.7% (15.1% to 22.9%) among those who did not. Compared with patients who did not receive prophylactic anticoagulation, those who did had a 27% decreased risk for 30 day mortality (hazard ratio 0.73, 95% confidence interval 0.66 to 0.81). Similar associations were found for inpatient mortality and initiation of therapeutic anticoagulation. Receipt of prophylactic anticoagulation was not associated with increased risk of bleeding that required transfusion (hazard ratio 0.87, 0.71 to 1.05). Quantitative bias analysis showed that results were robust to unmeasured confounding (e-value lower 95% confidence interval 1.77 for 30 day mortality). Results persisted in several sensitivity analyses.
Conclusions: Early initiation of prophylactic anticoagulation compared with no anticoagulation among patients admitted to hospital with covid-19 was associated with a decreased risk of 30 day mortality and no increased risk of serious bleeding events. These findings provide strong real world evidence to support guidelines recommending the use of prophylactic anticoagulation as initial treatment for patients with covid-19 on hospital admission.
. 2021 Feb 11;372:n311.
doi: 10.1136/bmj.n311.
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Christopher T Rentsch[SUP] 1 2 [/SUP], Joshua A Beckman[SUP] 3 [/SUP], Laurie Tomlinson[SUP] 4 [/SUP], Walid F Gellad[SUP] 5 6 7 [/SUP], Charles Alcorn[SUP] 8 [/SUP], Farah Kidwai-Khan[SUP] 2 9 [/SUP], Melissa Skanderson[SUP] 2 [/SUP], Evan Brittain[SUP] 10 [/SUP], Joseph T King Jr[SUP] 2 11 [/SUP], Yuk-Lam Ho[SUP] 12 [/SUP], Svetlana Eden[SUP] 13 [/SUP], Suman Kundu[SUP] 14 [/SUP], Michael F Lann[SUP] 8 [/SUP], Robert A Greevy Jr[SUP] 15 [/SUP], P Michael Ho[SUP] 16 [/SUP], Paul A Heidenreich[SUP] 17 18 [/SUP], Daniel A Jacobson[SUP] 19 [/SUP], Ian J Douglas[SUP] 4 [/SUP], Janet P Tate[SUP] 2 9 [/SUP], Stephen J W Evans[SUP] 4 [/SUP], David Atkins[SUP] 20 [/SUP], Amy C Justice[SUP] 2 9 21 [/SUP], Matthew S Freiberg[SUP] 14 22 [/SUP]
Affiliations
- PMID: 33574135
- PMCID: PMC7876672
- DOI: 10.1136/bmj.n311
Abstract
Objective: To evaluate whether early initiation of prophylactic anticoagulation compared with no anticoagulation was associated with decreased risk of death among patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United States.
Design: Observational cohort study.
Setting: Nationwide cohort of patients receiving care in the Department of Veterans Affairs, a large integrated national healthcare system.
Participants: All 4297 patients admitted to hospital from 1 March to 31 July 2020 with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and without a history of anticoagulation.
Main outcome measures: The main outcome was 30 day mortality. Secondary outcomes were inpatient mortality, initiating therapeutic anticoagulation (a proxy for clinical deterioration, including thromboembolic events), and bleeding that required transfusion.
Results: Of 4297 patients admitted to hospital with covid-19, 3627 (84.4%) received prophylactic anticoagulation within 24 hours of admission. More than 99% (n=3600) of treated patients received subcutaneous heparin or enoxaparin. 622 deaths occurred within 30 days of hospital admission, 513 among those who received prophylactic anticoagulation. Most deaths (510/622, 82%) occurred during hospital stay. Using inverse probability of treatment weighted analyses, the cumulative incidence of mortality at 30 days was 14.3% (95% confidence interval 13.1% to 15.5%) among those who received prophylactic anticoagulation and 18.7% (15.1% to 22.9%) among those who did not. Compared with patients who did not receive prophylactic anticoagulation, those who did had a 27% decreased risk for 30 day mortality (hazard ratio 0.73, 95% confidence interval 0.66 to 0.81). Similar associations were found for inpatient mortality and initiation of therapeutic anticoagulation. Receipt of prophylactic anticoagulation was not associated with increased risk of bleeding that required transfusion (hazard ratio 0.87, 0.71 to 1.05). Quantitative bias analysis showed that results were robust to unmeasured confounding (e-value lower 95% confidence interval 1.77 for 30 day mortality). Results persisted in several sensitivity analyses.
Conclusions: Early initiation of prophylactic anticoagulation compared with no anticoagulation among patients admitted to hospital with covid-19 was associated with a decreased risk of 30 day mortality and no increased risk of serious bleeding events. These findings provide strong real world evidence to support guidelines recommending the use of prophylactic anticoagulation as initial treatment for patients with covid-19 on hospital admission.